Search

Your search keyword '"Poveda-Velasco, Andrés"' showing total 8 results
Start Over Author "Poveda-Velasco, Andrés"
8 results on '"Poveda-Velasco, Andrés"'

1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Friedlander, Michael, Harter, Philipp, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Oza, Amit, Poveda Velasco, Andrés, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Vidal Boixader, Laura, Scott, Clare, Tamura, Kenji, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, Dubot, Coraline, De La Motte Rouge, Thibault, Kaminsky, Marie-Christine, Weber, Béatrice, Lortholary, Alain, Parkinson, Christine, Ledermann, Jonathan, Williams, Sarah, Banerjee, Susana, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Floquet, Anne, Hirte, Holger, Amit, Amnon, Park-Simon, Tjoung-Won, Matsumoto, Koji, Tjulandin, Sergei, Hoon Kim, Jae, Gladieff, Laurence, Sabbatini, Roberto, O'Malley, David, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Barretina Ginesta, Maria Pilar, Tibau Martorell, Ariadna, Gómez De Liaño Lista, Alfonso, Ojeda González, Belén, Mileshkin, Linda, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Cognetti, Francesco, Warshal, David, Dickson-Michelson, Elizabeth, Kamelle, Scott, McKenzie, Nathalie, Rodriguez, Gustavo, Armstrong, Deborah, Chalas, Eva, Celano, Paul, Behbakht, Kian, Davidson, Susan, Welch, Stephen, Helpman, Limor, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Bidziński, Mariusz, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Gropp-Meier, Martina, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Weon Kim, Jae, Hegg, Roberto, Vergote, Ignace, Poveda, Andrés, Ledermann, Jonathan A, Asher, Rebecca, Penson, Richard T, Oza, Amit M, Baldoni, Alessandra, Sonke, Gabe S, Kim, Jae-Hoon, Filho, Elias Abdo, Milenkova, Tsveta, Lowe, Elizabeth S, Rowe, Phil, and Pujade-Lauraine, Eric

Published
2021
Full Text
View/download PDF

2. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Poveda, Andrés, primary, Floquet, Anne, additional, Ledermann, Jonathan A, additional, Asher, Rebecca, additional, Penson, Richard T, additional, Oza, Amit M, additional, Korach, Jacob, additional, Huzarski, Tomasz, additional, Pignata, Sandro, additional, Friedlander, Michael, additional, Baldoni, Alessandra, additional, Park-Simon, Tjoung-Won, additional, Tamura, Kenji, additional, Sonke, Gabe S, additional, Lisyanskaya, Alla, additional, Kim, Jae-Hoon, additional, Filho, Elias Abdo, additional, Milenkova, Tsveta, additional, Lowe, Elizabeth S, additional, Rowe, Phil, additional, Vergote, Ignace, additional, Pujade-Lauraine, Eric, additional, Byrski, Tomasz, additional, Pautier, Patricia, additional, Harter, Philipp, additional, Colombo, Nicoletta, additional, Scambia, Giovanni, additional, Nicoletto, Maria, additional, Nussey, Fiona, additional, Clamp, Andrew, additional, Penson, Richard, additional, Oza, Amit, additional, Poveda Velasco, Andrés, additional, Rodrigues, Manuel, additional, Lotz, Jean-Pierre, additional, Selle, Frédéric, additional, Ray-Coquard, Isabelle, additional, Provencher, Diane, additional, Prat Aparicio, Aleix, additional, Vidal Boixader, Laura, additional, Scott, Clare, additional, Yunokawa, Mayu, additional, Medioni, Jacques, additional, Pécuchet, Nicolas, additional, Dubot, Coraline, additional, De La Motte Rouge, Thibault, additional, Kaminsky, Marie-Christine, additional, Weber, Béatrice, additional, Lortholary, Alain, additional, Parkinson, Christine, additional, Ledermann, Jonathan, additional, Williams, Sarah, additional, Banerjee, Susana, additional, Cosin, Jonathan, additional, Hoffman, James, additional, Plante, Marie, additional, Covens, Allan, additional, Sonke, Gabe, additional, Joly, Florence, additional, Hirte, Holger, additional, Amit, Amnon, additional, Matsumoto, Koji, additional, Tjulandin, Sergei, additional, Hoon Kim, Jae, additional, Gladieff, Laurence, additional, Sabbatini, Roberto, additional, O'Malley, David, additional, Timmins, Patrick, additional, Kredentser, Daniel, additional, Laínez Milagro, Nuria, additional, Barretina Ginesta, Maria Pilar, additional, Tibau Martorell, Ariadna, additional, Gómez De Liaño Lista, Alfonso, additional, Ojeda González, Belén, additional, Mileshkin, Linda, additional, Mandai, Masaki, additional, Boere, Ingrid, additional, Ottevanger, Petronella, additional, Nam, Joo-Hyun, additional, Filho, Elias, additional, Hamizi, Salima, additional, Cognetti, Francesco, additional, Warshal, David, additional, Dickson-Michelson, Elizabeth, additional, Kamelle, Scott, additional, McKenzie, Nathalie, additional, Rodriguez, Gustavo, additional, Armstrong, Deborah, additional, Chalas, Eva, additional, Celano, Paul, additional, Behbakht, Kian, additional, Davidson, Susan, additional, Welch, Stephen, additional, Helpman, Limor, additional, Fishman, Ami, additional, Bruchim, Ilan, additional, Sikorska, Magdalena, additional, Słowińska, Anna, additional, Rogowski, Wojciech, additional, Bidziński, Mariusz, additional, Śpiewankiewicz, Beata, additional, Casado Herraez, Antonio, additional, Mendiola Fernández, César, additional, Gropp-Meier, Martina, additional, Saito, Toshiaki, additional, Takehara, Kazuhiro, additional, Enomoto, Takayuki, additional, Watari, Hidemichi, additional, Choi, Chel Hun, additional, Kim, Byoung-Gie, additional, Weon Kim, Jae, additional, and Hegg, Roberto, additional

Published
2021
Full Text
View/download PDF

3. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Pujade-Lauraine, Eric, primary, Ledermann, Jonathan A, additional, Selle, Frédéric, additional, Gebski, Val, additional, Penson, Richard T, additional, Oza, Amit M, additional, Korach, Jacob, additional, Huzarski, Tomasz, additional, Poveda, Andrés, additional, Pignata, Sandro, additional, Friedlander, Michael, additional, Colombo, Nicoletta, additional, Harter, Philipp, additional, Fujiwara, Keiichi, additional, Ray-Coquard, Isabelle, additional, Banerjee, Susana, additional, Liu, Joyce, additional, Lowe, Elizabeth S, additional, Bloomfield, Ralph, additional, Pautier, Patricia, additional, Byrski, Tomasz, additional, Scambia, Giovanni, additional, Nicoletto, Maria, additional, Nussey, Fiona, additional, Clamp, Andrew, additional, Penson, Richard, additional, Oza, Amit, additional, Poveda Velasco, Andrés, additional, Rodrigues, Manuel, additional, Lotz, Jean-Pierre, additional, Provencher, Diane, additional, Prat Aparicio, Aleix, additional, Vidal Boixader, Laura, additional, Scott, Clare, additional, Tamura, Kenji, additional, Yunokawa, Mayu, additional, Lisyanskaya, Alla, additional, Medioni, Jacques, additional, Pécuchet, Nicolas, additional, Dubot, Coraline, additional, de la Motte Rouge, Thibault, additional, Kaminsky, Marie-Christine, additional, Weber, Béatrice, additional, Lortholary, Alain, additional, Parkinson, Christine, additional, Ledermann, Jonathan, additional, Williams, Sarah, additional, Cosin, Jonathan, additional, Hoffman, James, additional, Plante, Marie, additional, Covens, Allan, additional, Sonke, Gabe, additional, Joly, Florence, additional, Floquet, Anne, additional, Hirte, Holger, additional, Amit, Amnon, additional, Park-Simon, Tjoung-Won, additional, Matsumoto, Koji, additional, Tjulandin, Sergei, additional, Kim, Jae Hoon, additional, Gladieff, Laurence, additional, Sabbatini, Roberto, additional, O'Malley, David, additional, Timmins, Patrick, additional, Kredentser, Daniel, additional, Laínez Milagro, Nuria, additional, Barretina Ginesta, Maria Pilar, additional, Tibau Martorell, Ariadna, additional, Gómez de Liaño Lista, Alfonso, additional, Ojeda González, Belén, additional, Mileshkin, Linda, additional, Mandai, Masaki, additional, Boere, Ingrid, additional, Ottevanger, Petronella, additional, Nam, Joo-Hyun, additional, Filho, Elias, additional, Hamizi, Salima, additional, Cognetti, Francesco, additional, Warshal, David, additional, Dickson-Michelson, Elizabeth, additional, Kamelle, Scott, additional, McKenzie, Nathalie, additional, Rodriguez, Gustavo, additional, Armstrong, Deborah, additional, Chalas, Eva, additional, Celano, Paul, additional, Behbakht, Kian, additional, Davidson, Susan, additional, Welch, Stephen, additional, Helpman, Limor, additional, Fishman, Ami, additional, Bruchim, Ilan, additional, Sikorska, Magdalena, additional, Słowińska, Anna, additional, Rogowski, Wojciech, additional, Bidziński, Mariusz, additional, Śpiewankiewicz, Beata, additional, Casado Herraez, Antonio, additional, Mendiola Fernández, César, additional, Gropp-Meier, Martina, additional, Saito, Toshiaki, additional, Takehara, Kazuhiro, additional, Enomoto, Takayuki, additional, Watari, Hidemichi, additional, Choi, Chel Hun, additional, Kim, Byoung-Gie, additional, Kim, Jae Weon, additional, Hegg, Roberto, additional, and Vergote, Ignace, additional

Published
2017
Full Text
View/download PDF

4. Documento de consenso de las sociedades científicas españolas. Vacunas profilácticas frente al VPH

Author

Cortés Bordoy, Javier, primary, de Paredes, Marisa García, additional, Muñoz Zato, Ernesto, additional, Martinón Torres, Federico, additional, Torné Blade, Aureli, additional, García Rojas, Amós, additional, Cisterna Cáncer, Ramón, additional, Antonio Vidart Aragón, José, additional, Abizanda González, Mercedes, additional, Ángel Pipoll Lozano, Miguel, additional, Vilaplana Vilaplana, Eduardo, additional, and Poveda Velasco, Andrés, additional

Published
2009
Full Text
View/download PDF

5. Tercer Consenso Nacional de Cáncer de Ovario 2011 Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM".

Author

Gallardo-Rincón, Dolores, Cantú-de-León, David, Alanís-López, Patricia, Ángel Álvarez-Avitia, Miguel, Bañuelos-Flores, Joel, Sidney Herbert-Núñez, Guillermo, Fernando Oñate-Ocaña, Luis, Delia Pérez-Montiel, María, Rodríguez-Trejo, Amelia, Ruvalcaba-Limón, Eva, Serrano-Olvera, Alberto, Ortega-Rojo, Andrea, Cortés-Esteban, Patricia, Erazo-Valle, Aura, Gerson-Cwilich, Raquel, De-la-Garza-Salazar, Jaime, Green-Renner, Dan, León-Rodríguez, Eucario, Morales-Vásquez, Flavia, and Poveda-Velasco, Andrés

Published
2011

6. Primer Consenso Mexicano de Cáncer de Endometrio Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM".

Author

Ruvalcaba-Limón, Eva, Cantú-de-León, David, León-Rodríguez, Eucario, Cortés-Esteban, Patricia, Serrano-Olvera, Alberto, Morales-Vásquez, Flavia, Sosa-Sánchez, Ricardo, Poveda-Velasco, Andrés, Crismatt-Zapata, Alejandro, Santillán-Gómez, Antonio, Aguilar-Jiménez, Carmen, Alanís-López, Patricia, Alfaro-Ramírez, Paulino, Ángel Álvarez-Avitia, Miguel, Eduardo Aranda-Flores, Carlos, Reynaldo Arias-Ceballos, José Héctor, Arrieta-Rodríguez, Oscar, Barragán-Curiel, Eduardo, Botello-Hernández, Daniel, and Brom-Valladares, Rocío

Published
2010

7. [Third National Ovarian Consensus. 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"].

Author

Gallardo-Rincón D, Cantú-de-León D, Alanís-López P, Alvarez-Avitia MA, Bañuelos-Flores J, Herbert-Núñez GS, Oñate-Ocaña LF, Pérez-Montiel MD, Rodríguez-Trejo A, Ruvalcaba-Limón E, Serrano-Olvera A, Ortega-Rojo A, Cortés-Esteban P, Erazo-Valle A, Gerson-Cwilich R, De-la-Garza-Salazar J, Green-Renner D, León-Rodríguez E, Morales-Vásquez F, Poveda-Velasco A, Aguilar-Ponce JL, Alva-López LF, Alvarado-Aguilar S, Alvarado-Cabrero I, Aquino-Mendoza CA, Aranda-Flores CE, Bandera-Delgado A, Barragán-Curiel E, Barrón-Rodríguez P, Brom-Valladares R, Cabrera-Galeana PA, Calderillo-Ruiz G, Camacho-Gutiérrez S, Capdeville-García D, Cárdenas-Sánchez J, Carlón-Zárate E, Carrillo-Garibaldi O, Castorena-Roji G, Cervantes-Sánchez G, Coronel-Martínez JA, Chanona-Vilchis JG, Díaz-Hernández V, Escudero-de-los Ríos P, Garibay-Cerdenares O, Gómez-García E, Herrera-Montalvo LA, Hinojosa-García LM, Isla-Ortiz D, Jiménez-López J, Lavín-Lozano AJ, Limón-Rodriguez JA, López-Basave HN, López-García SC, Maffuz-Aziz A, Martínez-Cedillo J, Martínez-López DM, Medina-Castro JM, Melo-Martínez C, Méndez-Herrera C, Montalvo-Esquivel G, Morales-Palomares MA, Morán-Mendoza A, Morgan-Villela G, Mota-García A, Muñoz-González DE, Ochoa-Carrillo FJ, Pérez-Amador M, Recinos-Money E, Rivera-Rivera S, Robles Flores JU, Rojas-Castillo E, Rojas-Marín C, Salas-Gonzáles E, Sámano-Nateras L, Santibañez-Andrade M, Santillán-Gómez A, Silva-García A, Silva JA, Solorza-Luna G, Tabarez-Ortiz AR, Talamás-Rohana P, Tirado-Gómez LL, Torres-Lobatón A, and Quijano-Castro F

Subjects
Aftercare, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant, Combined Modality Therapy, Drug Resistance, Neoplasm, Early Diagnosis, Female, Genes, Neoplasm, Humans, Laparoscopy, Lymph Node Excision, Neoadjuvant Therapy, Neoplasm Staging standards, Neoplastic Syndromes, Hereditary genetics, Omentum surgery, Organoplatinum Compounds administration & dosage, Ovariectomy methods, Palliative Care, Quality of Life, Radiotherapy, Adjuvant, Salvage Therapy, Taxoids administration & dosage, Ovarian Neoplasms diagnosis, Ovarian Neoplasms epidemiology, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy
Abstract

Introduction: Ovarian cancer (OC) is the third most common gynecologic malignancy worldwide. Most of cases it is of epithelial origin. At the present time there is not a standardized screening method, which makes difficult the early diagnosis. The 5-year survival is 90% for early stages, however most cases present at advanced stages, which have a 5-year survival of only 5-20%. GICOM collaborative group, under the auspice of different institutions, have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia., Material and Methods: The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of two days in which a debate was held. These statements are the conclusions reached by agreement of the participant members., Results: No screening method is recommended at the time for the detection of early lesions of ovarian cancer in general population. Staging is surgical, according to FIGO. In regards to the pre-surgery evaluation of the patient, it is recommended to perform chest radiography and CT scan of abdomen and pelvis with IV contrast. According to the histopathology of the tumor, in order to consider it as borderline, the minimum percentage of proliferative component must be 10% of tumor's surface. The recommended standardized treatment includes primary surgery for diagnosis, staging and cytoreduction, followed by adjuvant chemotherapy Surgery must be performed by an Oncologist Gynecologist or an Oncologist Surgeon because inadequate surgery performed by another specialist has been reported in 75% of cases. In regards to surgery it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10-30% of all cases, and systematic limphadenectomy, necessary to be able to obtain an adequate surgical staging. Fertility-sparing surgery will be performed in certain cases, the procedure should include a detailed inspection of the contralateral ovary and also negative for malignancy omentum and ovary biopsy. Until now, laparoscopy for diagnostic-staging surgery is not well known as a recommended method. The recommended chemotherapy is based on platin and taxanes for 6 cycles, except in Stage IA, IB and grade 1, which have a good prognosis. In advanced stages, primary cytoreduction is recommended as initial treatment. Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer. Radiotherapy can be used to palliate symptoms. Follow up of the patients every 2-4 months for 2 years, every 3-6 months for 3 years and anually after the 5th year is recommended. Evaluation of quality of life of the patient must be done periodically., Conclusions: In the present, there is not a standardized screening method. Diagnosis in early stages means a better survival. Standardized treatment includes primary surgery with the objective to perform an optimal cytoreduction followed by chemotherapy Treatment must be individualized according to each patient. Radiotherapy can be indicated to palliate symptoms.

Published
2011

8. [The first Mexican consensus of endometrial cancer. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México].

Author

Ruvalcaba-Limón E, Cantú-de-León D, León-Rodríguez E, Cortés-Esteban P, Serrano-Olvera A, Morales-Vásquez F, Sosa-Sánchez R, Poveda-Velasco A, Crismatt-Zapata A, Santillán-Gómez A, Aguilar-Jiménez C, Alanís-López P, Alfaro-Ramírez P, Alvarez-Avitia MA, Aranda-Flores CE, Arias-Ceballos JH, Arrieta-Rodríguez O, Barragán-Curiel E, Botello-Hernández D, Brom-Valladares R, Cabrera-Galeana PA, Cantón-Romero JC, Capdeville-García D, Cárdenas-Sánchez J, Castorena-Roji G, Cepeda-López FR, Cervantes-Sánchez G, Cetina-Pérez Lde C, Coronel-Martínez JA, Cortés-Cárdenas SA, Cruz-López JC, de la Garza-Salazar JG, Díaz-Romero C, Dueñas-González A, Valle-Solís AE, Escudero-de los Ríos P, Flores-Alvarez E, García-Matus R, Gerson-Cwilich R, González-Enciso A, González-de-León C, Guevara-Torres AG, Herbert-Núñez GS, Hernández-Hernández C, Hernández-Hernández DM, Isla-Ortiz D, Jesús-Sandoval R, Jiménez-Cervantes C, Kuri-Exsome R, López-Obispo JL, Maffuz-Aziz A, Martínez-Barrera LM, Medina-Castro JM, Montalvo-Esquivel G, Mora-Aguilar VH, Morales-Palomares MA, Morán-Mendoza A, Morgan-Villela G, Mota-García A, Muñoz-González DE, Murillo-Cruz DA, Novoa-Vargas A, Ochoa-Carrillo FJ, Oñate-Ocaña LF, Ortega-Rojo A, Palacios-Martínez AG, Palomeque-López A, Pérez-Montiel MD, Quijano-Castro F, Rivera-Rivera S, Rivera-Rubí LM, Robles-Flores JU, Rodríguez-Trejo A, Salas-Gonzáles E, Silva JA, Solorza-Luna G, Souto-del-Bosque R, Tirado-Gómez LL, Torrescano-González S, Torres-Lobatón A, Trejo-Durán E, Villavicencio-Valencia V, and Gallardo-Rincón D

Subjects
Antineoplastic Agents therapeutic use, Chemotherapy, Adjuvant, Combined Modality Therapy, Diagnostic Imaging, Estrogen Antagonists adverse effects, Estrogen Replacement Therapy adverse effects, Estrogens adverse effects, Evidence-Based Medicine, Female, Humans, Hysterectomy methods, Laparoscopy, Lymph Node Excision, Mass Screening, Mexico, Neoplasm Staging methods, Radiotherapy, Adjuvant, Risk Factors, Salvage Therapy, Tamoxifen adverse effects, Carcinoma diagnosis, Carcinoma epidemiology, Carcinoma pathology, Carcinoma therapy, Endometrial Neoplasms diagnosis, Endometrial Neoplasms epidemiology, Endometrial Neoplasms pathology, Endometrial Neoplasms therapy
Abstract

Introduction: Endometrial cancer (EC) is the second most common gynecologic malignancy worldwide in the peri and postmenopausal period. Most often for the endometrioid variety. In early clinical stages long-term survival is greater than 80%, while in advanced stages it is less than 50%. In our country there is not a standard management between institutions. GICOM collaborative group under the auspice of different institutions have made the following consensus in order to make recommendations for the management of patients with this type of neoplasm., Material and Methods: The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of four days in which a debate was held. These statements are the conclusions reached by agreement of the participant members., Results: Screening should be performed women at high risk (diabetics, family history of inherited colon cancer, Lynch S. type II). Endometrial thickness in postmenopausal patients is best evaluated by transvaginal US, a thickness greater than or equal to 5 mm must be evaluated. Women taking tamoxifen should be monitored using this method. Abnormal bleeding in the usual main symptom, all post menopausal women with vaginal bleeding should be evaluated. Diagnosis is made by histerescopy-guided biopsy. Magnetic resonance is the best image method as preoperative evaluation. Frozen section evaluates histologic grade, myometrial invasion, cervical and adnexal involvement. Total abdominal hysterectomy, bilateral salpingo oophorectomy, pelvic and para-aortic lymphadenectomy should be performed except in endometrial histology grades 1 and 2, less than 50% invasion of the myometrium without evidence of disease out of the uterus. Omentectomy should be done in histologies other than endometriod. Surgery should be always performed by a Gynecologic Oncologist or Surgical Oncologist, laparoscopy is an alternative, especially in patients with hypertension and diabetes for being less morbid. Adjuvant treatment after surgery includes radiation therapy to the pelvis, brachytherapy, and chemotherapy. Patients with Stages III and IV should have surgery with intention to achieve optimal cytoreduction because of the impact on survival (51 m vs. 14 m), the treatment of recurrence can be with surgery depending on the pattern of relapse, systemic chemotherapy or hormonal therapy. Follow-up of patients is basically clinical in a regular basis., Conclusions: Screening programme is only for high risk patients. Multidisciplinary treatment impacts on survival and local control of the disease, including surgery, radiation therapy and chemotherapy, hormonal treatment is reserved to selected cases of recurrence. This is the first attempt of a Mexican Collaborative Group in Gynecology to give recommendations is a special type of neoplasm.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results